Asset

ALENDRONATE SODIUM

Organon & Co. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (5)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00092040phase3completed2003-03-182004-10-18Organon and CoA Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)
NCT00803790phase1completed2006-05-012006-07-01Organon and CoA Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)
NCT00398606phase3completed1995-04-011998-02-01Organon and CoA Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)
NCT00092027phase3completed2003-03-192004-03-15Organon and CoA Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)
NCT00398931phase3completed1998-02-012003-10-01Organon and CoFLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)

FDA applications (2)

ApplicationTypeApplicant
NDA 020560NDAORGANON LLC A SUB OF ORGANON AND CO
NDA 021762NDAORGANON LLC

Marketed products (7)

  • FOSAMAX
  • FOSAMAX
  • FOSAMAX
  • FOSAMAX
  • FOSAMAX
  • FOSAMAX PLUS D
  • FOSAMAX PLUS D